Table 3.
Other Medication and Dispositional Preferences for the Management of Hyphema
| N=36 | All Hyphema (N, %) |
|---|---|
| Routinely administer topical cycloplegicsa | 34 (94.4%) |
| Atropine 1% | 21 (58.3%) |
| Cyclopentolate 1–2% | 13 (36.1%) |
| Otherb | 7 (19.4%) |
| Do not administer antifibrinolytics | 36 (100.0%) |
| Routinely discontinue anticoagulation or anti-platelet medicationsc | 15 (41.7%) |
| Activity modificationsd | |
| Elevate head and sleep upright | 31 (86.1%) |
| Partial bed rest | 21 (58.3%) |
| Shielding of eye | 19 (52.8%) |
| Complete bed rest | 8 (22.2%) |
| Minor activity limitations | 6 (16.7%) |
| Othere | 1 (2.8%) |
| No activity limitations | 0 (0.0%) |
| Routinely screen for sickle cell disease/trait | 6 (16.7%) |
| Routine disposition of hyphema patients | |
| Admitted to hospital | 8 (22.2%) |
| Discharged without admitting | 25 (69.4%) |
| Otherf | 3 (8.3%) |
Notes: aOne respondent selected “Do Not Know”, bother responses included homatropine, tropicamide (± phenylephrine), variable, cif deemed safe by primary care provider, other responses included depending on PCP advice, in patients with significant rebleeds, depending on the reason for anticoagulation, and that the decision is highly variable, drespondents could select more than one option, eother response stated that activity limitation depended on grade, fother responses included depending on IOP and blood amount.